rheinmetall_panther

Rheinmetall earnings: waiting for Europe’s rearmament to fire

Jacob Falkencrone 400x400
Jacob Falkencrone

Global Head of Investment Strategy

Key points:

  • Q2 softness was driven by political delays, not demand weakness, with a record EUR 63 billion backlog supporting future growth.
  • Major German orders are expected in Q4, likely boosting revenue, margins, and potentially triggering a guidance upgrade.
  • Valuation is demanding, so future gains depend on flawless execution and contract delivery.


Germany’s Rheinmetall has become a symbol of Europe’s new defence era—an industrial cornerstone of NATO’s rearmament drive and one of the biggest winners of the post-Ukraine geopolitical reset. But in its latest earnings release, the continent’s most valuable arms manufacturer revealed what happens when strategy collides with politics: strong long-term prospects, but a short-term stall.

“The defence cycle is real, but not linear. Rheinmetall’s growth story is intact—but this quarter was a pause, not a pivot.”

Steady results meet political headwinds

In the second quarter, Rheinmetall reported sales of EUR 2.43 billion—up 8.8% year-on-year but shy of expectations around EUR 2.52 billion. Operating profit came in at EUR 276 million, modestly higher than last year’s EUR 270 million. But operating margins slipped to 11.3%, down from 12.1% in Q2 2024. That moderation in growth stands in stark contrast to Q1’s explosive results—46% sales growth. Net profit, however, more than doubled to EUR 159 million, highlighting operational resilience.

Rheinmetall shares fell more than 5% after the release, as markets reacted to the softer-than-expected top line and order intake—even as the company reaffirmed its full-year guidance.

The real story wasn’t the revenue—it was the absence of expected orders. Order intake came in weaker than anticipated as Germany’s delayed budget process pushed defence contracts into the second half.

This quarter was less about demand—and more about delayed signatures in Berlin.”

Political delays, not demand decay

Germany’s post-election transition and delayed budget approval have slowed the rollout of new defence contracts. With procurement effectively on hold, Rheinmetall saw expected orders pushed into the second half of the year. Once parliament finalises the 2025 budget after the summer break, order flow is expected to pick up sharply—especially after Chancellor Merz loosened the country’s fiscal rules to allow more aggressive defence spending.

Despite that, the company’s order backlog reached a new all-time high of EUR 63.2 billion. It’s more than six times its annual sales—and it’s still growing.

CEO Armin Papperger remains confident: "Our order books are full and will continue to grow." Germany’s defence budget is set to rise 70% by 2029, and NATO’s pledge to raise spending to 5% of GDP across member states only adds more firepower to future expectations.

“This wasn’t a demand problem—it was a paperwork problem. The backlog is strong, so quarterly softness is just the noise.”

Segment performance: shells lead the charge

Rheinmetall’s strength lies in its weapons and ammunition segment, which posted 25.6% year-on-year sales growth in H1. Demand for 155mm artillery shells and NATO-standard ammunition continues to surge, driven by Ukraine support and NATO stockpiling.

Vehicle systems also delivered solid performance, with H1 sales up 46%. But there are pressure points. Free cash flow turned deeply negative at minus EUR 911 million in Q2, driven by inventory build-up and aggressive capex—a key area for investors to watch.

Holding guidance—at least for now

Despite the soft quarter, Rheinmetall reaffirmed its full-year guidance: 25–30% revenue growth and a 15.5% operating margin. Management noted that this forecast doesn’t yet reflect the potential uplift from rising defence budgets across Europe.

Most analysts expect a guidance upgrade later this year, assuming contract delays resolve as expected. The real test will come in Q4, when Berlin’s procurement engine is finally set to restart.

Execution needs to catch up to expectations

Rheinmetall is scaling fast to meet Europe’s rearmament needs—investing in new ammunition and F-35 component factories, while expanding into India and Spain through strategic partnerships. These moves position it as a long-term defence cornerstone for NATO and its allies.

Rheinmetall trades at a forward P/E of around 57x—well above its historical average. This elevated multiple reflects delayed contract execution and front-loaded investments rather than current earnings strength.

Investors should watch closely: if contract deliveries ramp up and earnings catch up in H2, the multiple could normalise. But if delays persist or margins disappoint, there’s little room for error at these levels.

“At 57x forward earnings, the story has to play out as expected—there’s no cheap entry here.”

What investors should watch

  1. Q4 contract awards: This will be the decisive moment. If Germany’s delayed orders land as expected, Rheinmetall’s full-year numbers could surprise to the upside.
  2. Cash flow recovery: Watch whether the H2 ramp-up in deliveries converts backlog into cash. Negative cash flows cannot be a trend.
  3. Margin stabilisation: Especially in non-defence and electronic units, where profitability slipped.
  4. Execution on capex: New factories must deliver. Slippage here could cap future earnings.
  5. Macro and politics: Defence is cyclical and highly sensitive to elections, policy shifts, and geopolitical risk. Watch for both tailwinds—and crosswinds.

A strong position, but priced for perfection

Rheinmetall’s Q2 didn’t impress the market, and the stock fell accordingly. But beneath the surface is a company positioned at the centre of one of Europe’s most powerful structural trends: rearmament. The delays are frustrating—but they’re not demand destruction. In defence, politics isn’t noise—it’s part of the cycle.

For investors, Rheinmetall is no longer the under-the-radar trade it was in 2022. But it still stands out as a rare structural growth story in European industry—anchored in rising defence budgets, NATO’s strategic reset, and the remilitarisation of the continent.

That said, caution is warranted. At current valuation levels, much of the optimism is already priced in—and execution will need to be flawless for the stock to justify its premium.

“This is no longer a cheap bet on a hot theme—it’s a position that needs to deliver. With expectations this high, the story needs to stay on track and there’s little room for disappointment.”





This material is marketing content and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results.

The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.

 

 

Outrageous Predictions 2026

01 /

  • Executive Summary: Outrageous Predictions 2026

    Outrageous Predictions

    Executive Summary: Outrageous Predictions 2026

    Saxo Group

    Read Saxo's Outrageous Predictions for 2026, our latest batch of low probability, but high impact ev...
  • A Fortune 500 company names an AI model as CEO

    Outrageous Predictions

    A Fortune 500 company names an AI model as CEO

    Charu Chanana

    Chief Investment Strategist

    Can AI be trusted to take over in the boardroom? With the right algorithms and balanced human oversi...
  • Dollar dominance challenged by Beijing’s golden yuan

    Outrageous Predictions

    Dollar dominance challenged by Beijing’s golden yuan

    Charu Chanana

    Chief Investment Strategist

    Beijing does an end-run around the US dollar, setting up a framework for settling trade in a neutral...
  • Obesity drugs for everyone – even for pets

    Outrageous Predictions

    Obesity drugs for everyone – even for pets

    Jacob Falkencrone

    Global Head of Investment Strategy

    The availability of GLP-1 drugs in pill form makes them ubiquitous, shrinking waistlines, even for p...
  • Dumb AI triggers trillion-dollar clean-up

    Outrageous Predictions

    Dumb AI triggers trillion-dollar clean-up

    Jacob Falkencrone

    Global Head of Investment Strategy

    Agentic AI systems are deployed across all sectors, and after a solid start, mistakes trigger a tril...
  • Quantum leap Q-Day arrives early, crashing crypto and destabilizing world finance

    Outrageous Predictions

    Quantum leap Q-Day arrives early, crashing crypto and destabilizing world finance

    Neil Wilson

    Investor Content Strategist

    A quantum computer cracks today’s digital security, bringing enough chaos with it that Bitcoin crash...
  • Taylor Swift-Kelce wedding spikes global growth

    Outrageous Predictions

    Taylor Swift-Kelce wedding spikes global growth

    John J. Hardy

    Global Head of Macro Strategy

    Next year’s most anticipated wedding inspires Gen Z to drop the doomscrolling and dial up the real w...
  • SpaceX announces an IPO, supercharging extraterrestrial markets

    Outrageous Predictions

    SpaceX announces an IPO, supercharging extraterrestrial markets

    John J. Hardy

    Global Head of Macro Strategy

    Financial markets go into orbit, to the moon and beyond as SpaceX expands rocket launches by orders-...
  • Britain’s Great EU Backdoor Return

    Outrageous Predictions

    Britain’s Great EU Backdoor Return

    Neil Wilson

    Investor Content Strategist

    Faced with rolling fiscal, economic, trade and political crises the UK government sneaks back into t...
  • Despite concerns, U.S. 2026 mid-term elections proceed smoothly

    Outrageous Predictions

    Despite concerns, U.S. 2026 mid-term elections proceed smoothly

    John J. Hardy

    Global Head of Macro Strategy

    In spite of outstanding threats to the American democratic process, the US midterms come and go cord...

This content is marketing material. 

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Market Ltd. (SCML) provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice or a recommendation.

SCML content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

SCML partners with companies that provide compensation for promotional activities conducted on its platform. Some partners also pay retrocessions contingent on clients investing in products from those partners. 

While SCML receives compensation from these partnerships, all educational and research content remains focused on providing information to clients.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. SCML does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992